{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:56:26Z","timestamp":1760057786798,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>In the introduction to his 1970 textbook BIOCHEMISTRY, Albert Lehninger wrote \u201cLiving things are composed of lifeless molecules [...]<\/jats:p>","DOI":"10.3390\/biom15030328","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:46:57Z","timestamp":1740383217000},"page":"328","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FOP: From Biomolecules to Hope"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1277-5420","authenticated-orcid":false,"given":"Frederick S.","family":"Kaplan","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"},{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"},{"name":"Center for Research in FOP and Related Disorders, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Pignolo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"unstructured":"Lehninger, A.L. (1970). Biochemistry. Pps. 833, Worth Publishers, Inc.","key":"ref_1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000365770","article-title":"Fibrodysplasia ossificans progressiva: Clinical course, genetic mutations and genotype-phenotype correlation","volume":"5","year":"2014","journal-title":"Mol. Syndromol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","article-title":"A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva","volume":"38","author":"Shore","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_4","first-page":"247","article-title":"Heterotopic ossification in mouse models of fibrodysplasia ossificans progressiva","volume":"Volume 1891","author":"Chakkalakal","year":"2019","journal-title":"Bone Morphogenetic Proteins: Methods in Molecular Biology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/humu.20868","article-title":"Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1","volume":"30","author":"Kaplan","year":"2009","journal-title":"Hum. Mutat."},{"doi-asserted-by":"crossref","unstructured":"Mejias Rivera, L., Shore, E.M., and Mourkioti, F. (2024). Cellular and molecular mechanisms of heterotopic ossification in fibrodysplasia ossificans progressiva. Biomedicines, 12.","key":"ref_6","DOI":"10.3390\/biomedicines12040779"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41422-023-00918-9","article-title":"The roles and regulatory mechanisms of TGF-\u03b2 and BMP signaling in bone and cartilage development, homeostasis and disease","volume":"34","author":"Wu","year":"2024","journal-title":"Cell Res."},{"doi-asserted-by":"crossref","unstructured":"Kaplan, F.S., Shore, E.M., and Pignolo, R.J. (2024). Fibrodysplasia ossificans progressiva emerges from obscurity. Trends Mol. Med.","key":"ref_8","DOI":"10.1016\/j.molmed.2024.08.010"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cytogfr.2009.10.021","article-title":"Applications of small molecule BMP inhibitors in physiology and disease","volume":"20","author":"Hong","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"eabp8334","DOI":"10.1126\/scitranslmed.abp8334","article-title":"An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva","volume":"16","author":"Davis","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e95042","DOI":"10.1172\/jci.insight.95042","article-title":"Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva","volume":"6","author":"Williams","year":"2021","journal-title":"JCI Insight"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nm.2334","article-title":"Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-\u03b3 agonists","volume":"17","author":"Shimono","year":"2011","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jbmr.4762","article-title":"Reduction of new heterotopic ossification (HO) in the open-label, phase 3 MOVE trial of palovarotene for fibrodysplasia ossificans progressiva (FOP)","volume":"38","author":"Pignolo","year":"2023","journal-title":"J. Bone Miner. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/s41591-023-02561-8","article-title":"Garetosmab in fibrodysplasia ossificans progressiva: A randomized, double-blind, placebo-controlled phase 2 trial","volume":"29","author":"Pignolo","year":"2023","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jbmr\/zjae029","article-title":"Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice","volume":"39","author":"Lounev","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/jbmr\/zjae044","article-title":"Actionable disease insights from bedside-to-bench investigation in fibrodysplasia ossificans progressiva","volume":"39","author":"Wein","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.gim.2022.08.013","article-title":"The natural history of fibrodysplasia ossificans progressiva: A prospective, global 36-month study","volume":"24","author":"Pignolo","year":"2022","journal-title":"Genet. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/437491a","article-title":"Pharmaceuticals: A new grammar for drug discovery","volume":"437","author":"Fishman","year":"2005","journal-title":"Nature"},{"doi-asserted-by":"crossref","unstructured":"Towler, O.W., Shore, E.M., and Kaplan, F.S. (2024). Molecular developmental biology of fibrodysplasia ossificans progressiva: Measuring the giant by its toe. Biomolecules, 14.","key":"ref_19","DOI":"10.3390\/biom14081009"},{"doi-asserted-by":"crossref","unstructured":"Diolintzi, A., Pervin, M.S., and Hsiao, E.C. (2024). Immunologic aspects in fibrodysplasia ossificans progressiva. Biomolecules, 14.","key":"ref_20","DOI":"10.3390\/biom14030357"},{"doi-asserted-by":"crossref","unstructured":"Pignolo, R.J., Kaplan, F.S., and Wang, H. (2024). Cell senescence in heterotopic ossification. Biomolecules, 14.","key":"ref_21","DOI":"10.3390\/biom14040485"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/jbmr.2848","article-title":"Cellular hypoxia promotes heterotopic ossification by amplifying BMP signaling","volume":"31","author":"Wang","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E338","DOI":"10.1073\/pnas.1515397113","article-title":"Inhibition of Hif1\u03b1 prevents both trauma-induced and genetic heterotopic ossification","volume":"113","author":"Agarwal","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"doi-asserted-by":"crossref","unstructured":"Wang, H., Kaplan, F.S., and Pignolo, R.J. (2024). The HIF-1\u03b1 and mTOR pathways amplify heterotopic ossification. Biomolecules, 14.","key":"ref_24","DOI":"10.3390\/biom14020147"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","article-title":"ACVR1 R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A","volume":"7","author":"Hatsell","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1172\/JCI93521","article-title":"Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva","volume":"127","author":"Hino","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bone.2017.06.011","article-title":"The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva","volume":"109","author":"Idone","year":"2018","journal-title":"Bone"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41467-018-02872-2","article-title":"Activin-dependent signaling in fibro\/adipogenic progenitors causes fibrodysplasia ossificans progressiva","volume":"9","author":"Yamamoto","year":"2018","journal-title":"Nat. Commun."},{"doi-asserted-by":"crossref","unstructured":"Srinivasan, D., Arostegui, M., Goebel, E.J., Hart, K.N., Aykul, S., Lees-Shepard, J.B., Idone, V., Hatsell, S.J., and Economides, A.N. (2024). How Activin A became a therapeutic Target in fibrodysplasia ossificans progressiva. Biomolecules, 14.","key":"ref_29","DOI":"10.3390\/biom14010101"},{"doi-asserted-by":"crossref","unstructured":"Cong, Q., and Yang, Y. (2024). Hedgehog signaling controls chondrogenesis and ectopic bone formation via the Yap-Ihh axis. Biomolecules, 14.","key":"ref_30","DOI":"10.3390\/biom14030347"},{"doi-asserted-by":"crossref","unstructured":"Groppe, J.C., Lu, G., Tandang-Silvas, M.R., Pathi, A., Konda, S., Wu, J., Le, V.Q., Culbert, A.L., Shore, E.M., and Wharton, K.A. (2023). Polypeptide substrate accessibility hypothesis: Gain-of-function R206H mutation allosterically affects activin receptor-like protein kinase activity. Biomolecules, 13.","key":"ref_31","DOI":"10.3390\/biom13071129"},{"doi-asserted-by":"crossref","unstructured":"Burdick, L.N., DelVichio, A.H., Hanson, L.R., Griffith, B.B., Bouchard, K.R., Hunter, J.W., and Goldhamer, D.J. (2024). Sex as a critical variable in basic and pre-clinical studies of fibrodysplasia ossificans progressiva. Biomolecules, 14.","key":"ref_32","DOI":"10.3390\/biom14020177"},{"doi-asserted-by":"crossref","unstructured":"Zwama, J., Rosenberg, N.M., Verheij, V.A., Raijmakers, P.G.H.M., Yaqub, M., Botman, E., de Ruiter, R.D., Garrelfs, M.R., B\u00f6kenkamp, A., and Micha, D. (2024). [18F]NaF PET\/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders. Biomolecules, 14.","key":"ref_33","DOI":"10.3390\/biom14101276"},{"doi-asserted-by":"crossref","unstructured":"Yang, Y.S., Lin, C., Ma, H., Xie, J., Kaplan, F.S., Gao, G., and Shim, J.H. (2023). AAV-Mediated targeting of the Activin A-ACVR1R206H signaling in fibrodysplasia ossificans progressiva. Biomolecules, 13.","key":"ref_34","DOI":"10.3390\/biom13091364"},{"doi-asserted-by":"crossref","unstructured":"Juan, C., Bancroft, A.C., Choi, J.H., Nunez, J.H., Pagani, C.A., Lin, Y.S., Hsiao, E.C., and Levi, B. (2024). Intersections of fibrodysplasia ossificans progressiva and traumatic heterotopic ossification. Biomolecules, 14.","key":"ref_35","DOI":"10.3390\/biom14030349"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/3\/328\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:41:20Z","timestamp":1760028080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/3\/328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["biom15030328"],"URL":"https:\/\/doi.org\/10.3390\/biom15030328","relation":{},"ISSN":["2218-273X"],"issn-type":[{"type":"electronic","value":"2218-273X"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}